UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Apple Turns 50: From Garage Startup to AI Crossroads 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
 & Lead Plaintiff Deadline - March 27, 2017 - EconoTimes)
NEW YORK, March 23, 2017 -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against ReWalk Robotics Ltd. (“ReWalk” or the “Company”) (NASDAQ:RWLK) and certain of its officers, on behalf of a class who purchased ReWalk securities pursuant to the Company’s initial public offering (“IPO”) on or around September 12, 2014. Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/rwlk.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
ReWalk is a medical commercial bionic walking assistance system. The company designs, develops, and commercializes exoskeletons for wheelchair-bound individuals.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements in its Registration Statement and Prospectus issued in regards with the Initial Public Offering did not disclose material information, including that ReWalk could not comply with “special controls” requirements or to offer the U.S. Food and Drug Administration with a post market surveillance study. Once this information was made public, ReWalk stock price dropped, causing investors harm.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/rwlk or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in ReWalk you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
